Singular Health Group Ltd (ASX:SHG)

The Quarterly Activities and Appendix 4C Cash Flow Report for Singular Health Group Ltd for the quarter ended 30 September 2025 highlights several key financial and operational activities. The company reported a net cash outflow from operating activities amounting to $1,699,000, primarily due to research and development expenses, product manufacturing costs, advertising and marketing, staff costs, and administration and corporate expenses. Despite these expenses, Singular Health successfully raised $150,000 through capital raising and $220,000 through the exercise of share options. The company’s cash and cash equivalents stood at $12,211,000 at the end of the quarter. Additionally, the report outlines the company’s strategic expansion into the U.S. market, including the establishment of a U.S. subsidiary and the appointment of a Chief Commercial Officer to lead U.S. operations. Singular Health is also advancing its 3DICOM™ software for broader scale adoption and is engaging in significant discussions with major U.S. healthcare organizations and federal agencies to integrate its technologies into healthcare programs.